{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:21:44Z","timestamp":1791998504539,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CSA-SI\/0013\/2017"],"award-info":[{"award-number":["NMRC\/CSA-SI\/0013\/2017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CSA-SI\/0018\/2017"],"award-info":[{"award-number":["NMRC\/CSA-SI\/0018\/2017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/OFLCG\/003\/2018"],"award-info":[{"award-number":["NMRC\/OFLCG\/003\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/STaR\/020\/2013"],"award-info":[{"award-number":["NMRC\/STaR\/020\/2013"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/TCR\/015-NCC\/2016"],"award-info":[{"award-number":["NMRC\/TCR\/015-NCC\/2016"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jhep.2022.03.039","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T01:53:34Z","timestamp":1649987614000},"page":"683-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7509-5126","authenticated-orcid":false,"given":"Samuel","family":"Chuah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-6125","authenticated-orcid":false,"given":"Joycelyn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-7698","authenticated-orcid":false,"given":"Yuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Don","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-2346","authenticated-orcid":false,"given":"Martin","family":"Wasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neslihan A.","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghye","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-9452","authenticated-orcid":false,"given":"Seung Hyuck","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-1506","authenticated-orcid":false,"given":"Sheena","family":"Suthen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamirah","family":"A\u2019Azman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Gien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6964-1197","authenticated-orcid":false,"given":"Chun Jye","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillus","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharifah Nur","family":"Hazirah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Kai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Qi","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony K.H.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Yeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6308-9503","authenticated-orcid":false,"given":"Eui-Cheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-3922","authenticated-orcid":false,"given":"Su Pin","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5617-0936","authenticated-orcid":false,"given":"Valerie","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.03.039_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2022.03.039_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab vs. sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2022.03.039_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2022.03.039_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4012","article-title":"Nivolumab (NIVO)\u00a0+ ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"37","author":"Yau","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2022.03.039_bib5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.03.039_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41591-019-0736-4","article-title":"Single-cell genomic approaches for developing the next generation of immunotherapies","volume":"26","author":"Yofe","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2022.03.039_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.03.039_bib8","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2022.03.039_bib9","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/0008-5472.CAN-15-2658","article-title":"Membrane IL1alpha inhibits the development of hepatocellular carcinoma via promoting T- and NK-cell activation","volume":"76","author":"Lin","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2022.03.039_bib10","doi-asserted-by":"crossref","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","article-title":"Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses","volume":"114","author":"Chew","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2022.03.039_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41587-020-0532-1","article-title":"The Extended Polydimensional Immunome Characterization (EPIC) web-based reference and discovery tool for cytometry data","volume":"38","author":"Yeo","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2022.03.039_bib12","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","article-title":"CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jhep.2022.03.039_bib13","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.03.039_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fimmu.2017.00086","article-title":"Human tumor-infiltrating myeloid cells: phenotypic and functional diversity","volume":"8","author":"Elliott","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2022.03.039_bib15","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"Bottcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.03.039_bib16","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1172\/JCI45444","article-title":"Kruppel-like factor 4 regulates macrophage polarization","volume":"121","author":"Liao","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2022.03.039_bib17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nm.4314","article-title":"Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance","volume":"23","author":"Daley","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2022.03.039_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2022.03.039_bib19","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1158\/1078-0432.CCR-18-3016","article-title":"Immunotherapeutic blockade of macrophage clever-1 reactivates the CD8(+) T-cell response against immunosuppressive tumors","volume":"25","author":"Viitala","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2022.03.039_bib20","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1038\/onc.2010.260","article-title":"The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development","volume":"29","author":"Wolf","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2022.03.039_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcell.2019.00091","article-title":"TNFR1 and TNFR2 in the control of the Life and death balance of macrophages","volume":"7","author":"Wajant","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jhep.2022.03.039_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ebiom.2019.08.067","article-title":"Role of CXCR3 signaling in response to anti-PD-1 therapy","volume":"48","author":"Han","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhep.2022.03.039_bib23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/mi.2015.93","article-title":"CD4 T cells are required for both development and maintenance of disease in a new mouse model of reversible colitis","volume":"9","author":"Brasseit","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jhep.2022.03.039_bib24","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00262-015-1751-z","article-title":"Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients","volume":"64","author":"Yan","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jhep.2022.03.039_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.039_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121926","article-title":"Rationale of immunotherapy in hepatocellular carcinoma and its potential biomarkers","volume":"11","author":"Tai","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2022.03.039_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","author":"Sangro","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.039_bib28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","article-title":"Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer","volume":"36","author":"Ma","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2022.03.039_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2022.03.039_bib30","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2018.01613","article-title":"Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer","volume":"9","author":"Manjarrez-Orduno","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2022.03.039_bib31","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2022.03.039_bib32","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2022.03.039_bib33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2022.03.039_bib34","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.03.039_bib35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.03.039_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/ITT.S255224","article-title":"TNFR2: role in cancer Immunology and immunotherapy","volume":"10","author":"Yang","year":"2021","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.jhep.2022.03.039_bib37","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1084\/jem.20072707","article-title":"Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells","volume":"205","author":"Notley","year":"2008","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jhep.2022.03.039_bib38","doi-asserted-by":"crossref","first-page":"102460","DOI":"10.1016\/j.autrev.2020.102460","article-title":"Characterization of auto-immune hepatitis associated with the use of anti-TNFalpha agents: an analysis of 389 cases in VigiBase","volume":"19","author":"Vollmer","year":"2020","journal-title":"Autoimmun Rev"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822002331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822002331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:35Z","timestamp":1759175255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822002331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0168827822002331"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.03.039","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}